目的：检测吉非替尼治疗非小细胞肺癌（ NSCLC）前后血管内皮生长因子（ VEGF）、基质金属蛋白酶-9（MMP-9）与金属蛋白酶组织抑制剂（TIMP-1）的血清水平，探讨其变化规律与吉非替尼治疗疗效之间的关系。方法采用ELISA双抗体夹心法检测48例NSCLC患者采用吉非替尼治疗前后血清VEGF、MMP-9和TIMP-1的水平，并参照RECIST评价标准进行疗效评价。结果吉非替尼治疗前后血清VEGF水平无明显变化（ P ＞0．05），但治疗后血清MMP-9与TIMP-1水平与治疗前相比明显下降（ P ＜0．05）。有效组治疗前后血清VEGF水平无显著变化（ P ＞0．05），但有效组治疗后MMP-9和TIMP-1的血清水平与治疗前相比显著降低（ P ＜0．05）。而无效组血清VEGF、MMP-9与TIMP-1的水平均无明显变化（ P ＞0．05）。结论血清MMP-9与TIMP-1的表达水平很可能与吉非替尼治疗非小细胞肺癌的疗效相关，提示MMP-9和TIMP-1可以反映患者病情的变化，为病情的进展和预后提供依据。%Objective To observe the changes of expression levels of serum vascular endothelial growth factor (VEGF),matrix metalloproteinase-9(MMP-9) and tissue inhibitors of metalloproteinase (TIMP)-1 before and after treatment of non small cell lung carcinoma ( NSCLC) by gefitinib in order to explore the correlation between the changes and therapeutic effect.Methods The serum levels of VEGF ,MMP-9 and TIMP-1were detected by ELISA in 48 patients with NSCLC before and after treatment by gefitinib ,and the therapeutic effects were evaluated according to RECIST evaluation criterion.Results There were no significant differences in the serum levels of VEGF before and after treatment by gefitinib (P >0.05).However after treatment the serum levels of MMP-9 and TIMP-1 were obviously decreased ,as compared with those before treatment ( P<0.05).There were no obvious changes in serum levels of VEGF in valid group before and after treatment by gefitinib ( P >0.05),but after treatment the serum levels of MMP-9 and TIMP-1 were significantly decreased in valid group ,as compared with those before treatment( P <0.05).Furthermore there were no obvious changes in serum levels of VEGF ,MMP-9 and TIMP-1 before and after treatment in invalid group ( P >0.05).Conclusion The expression levels of serum MMP-9 and TIMP-1 may be correlated to the therapeutic effect of gefitinib on NSCLC ,whch suggests that MMP-9 and TIMP-1 may reflect the changes of patient ’ s condition and may be helpful for predicting the progress of NSCLC and prognosis of patients .
展开▼
